Company Filing History:
Years Active: 1993-2000
Title: James A. Monn: Innovator in Neuropsychopharmacology
Introduction: James A. Monn is a notable inventor based in Gaithersburg, Maryland, specializing in the field of neuropsychopharmacology. With a total of two patents to his name, Monn has made significant contributions to the treatment of neuropsychological disorders. His work has greatly impacted the methods available for addressing these complex conditions.
Latest Patents: Monn's latest inventions include "Partial Agonists of the Strychnine Insensitive Glycine Modulatory Site," which discloses a method for treating neuropsychopharmacological disorders linked to excessive activation of the N-methyl-D-aspartate receptor complex. This innovative method involves administering effective amounts of compounds that possess partial agonist properties for the strychnine insensitive glycine modulatory sites of N-methyl-D-aspartate receptors. Notably, it highlights 1-aminocyclopropanecarboxylic acid and associated derivatives as exemplary partial agonists.
Another significant patent is for "5-Aminocarbonyl-5H-Dibenzo[a.d]Cyclohepten-5,10-Imines for Treatment of Generalized Epilepsy." This invention involves compounds, compositions, and methods specifically aimed at treating patients with generalized or partial symptomatic epilepsy. Furthermore, it addresses methods for managing drug cravings in cocaine-addicted patients, showcasing Monn's commitment to improving mental health treatments.
Career Highlights: Monn works for the United States of America, as represented by the Department of Health. His role within this esteemed organization positions him at the forefront of clinical research and innovative drug development, where he contributes valuable insights into neuropsychopharmacological advancements.
Collaborations: Throughout his career, Monn has collaborated with key figures in his field, including Kenner C. Rice and Phil Skolnick. These collaborations have not only enhanced the research process but have also led to the advancement of treatment methodologies for various neurological conditions.
Conclusion: James A. Monn’s innovative work in the field of neuropsychopharmacology significantly contributes to our understanding and treatment of complex mental health disorders. His patents reflect a dedication to improving therapeutic approaches, making a lasting impact on clinical neurology and the lives of individuals facing these challenges.